Mice were injected subcutaneously (s.c.) with 25 μg of each peptide either as a pool or individually in combination with 5μg of CpG ODN 1826 (CpG) and Monophosphoryl Lipid A (MPLA) (InvivoGen) on days 1, 8 and 15 and responses analyzed on day 21.
For anti-tumor experiments, mice were implanted s.c. with tumor cells three days prior to immunization regime above. Implant doses were 5.0 x 105 cells/mouse for B16 HHDII/DR1, 2.5x104 cells/mouse for B16F1DR4 and 5x104 cells/mouse for B16F1 iDR4 and B16F1 h2Ab1 B2M dKO cell lines (17 (link), 31 (link), 32 (link)). Tumor growth was monitored twice weekly and mice were humanely euthanized once tumors approach the license limit of 15 mm in diameter.
For anti-tumor experiments, mice were implanted s.c. with tumor cells three days prior to immunization regime above. Implant doses were 5.0 x 105 cells/mouse for B16 HHDII/DR1, 2.5x104 cells/mouse for B16F1DR4 and 5x104 cells/mouse for B16F1 iDR4 and B16F1 h2Ab1 B2M dKO cell lines (17 (link), 31 (link), 32 (link)). Tumor growth was monitored twice weekly and mice were humanely euthanized once tumors approach the license limit of 15 mm in diameter.
Free full text: Click here
